MONTREAL, QUEBEC--(Marketwire - October 23, 2007) - Ambrilia Biopharma (TSX: AMB) announced today that the data of the Phase I/II clinical study conducted at the Memorial Sloan Kettering Cancer Centre (MSKCC) in New York City, was presented by Dr. Susan Slovin, co-investigator of the study, at the AACR-NCI-EORTC International Conference and by Dr. Chandra Panchal at the 2007 Annual Fall Conference on Antiangiogenesis.
